A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors

Inclusion criteria

• Patients with histologically verified diagnosis of dermoid tumor
• The presence of progressive, symptomatic or functionally significant DF.
• Written Informed consent to participate in the study
• Age from 18 to 75 years
• The functional status of the patient according to the ECOG 0-2 scale
• Normal renal function (estimated creatinine clearance 60 ml/min);
• Normal level of bilirubin and liver enzymes (AST, ALT - no more than 3 norms);
• Left ventricular ejection fraction > 55%
• Satisfactory bone marrow function (hemoglobin level 9 g/dl, neutrophil count 1.5 thousand/ml, platelet count < 100 thousand/ml);

Exclusion criteria

• The inability to obtain informed consent to participate in the study
• Synchronous or metachronous cancer
• Clinically significant diseases of the cardiovascular system
• Clinically significant CNS diseases
• Previous grade 2 polyneuropathy and above
• Current infection or other severe or systemic disease that increases the risk of complications of therapy
• Pregnancy, lactation